- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Natco Pharma Limited — Updates, 03-02-2026: Press Release
03-02-2026 | 01:19 pm
03-02-2026 | 01:19 pm
NATCO Pharma received tentative approval for generic Erdafitinib tablets, a version of Balversa® for urothelial carcinoma. The branded drug saw estimated US sales of USD 60 million, indicating significant market potential.
No comments yet. Be the first to comment!